COL3A1 and Ehlers-Danlos syndrome, vascular type: In a more recent French study on knock-in Col3a1+/G182R mice leading to glycine substitution (the most common mutation observed in patients with vEDS), different antihypertensive therapies, alone or in combination, were compared in terms of effects on survival within the first 24 weeks of life [8].